Novartis (NYSE: NVS) is paying $1.1 billion upfront to buy Myricx Bio, a London-based biotech with its U.S. presence based in ...
CNBC’s Jim Cramer delivers his daily Mad Dash.
A Congressional investigation is looking into whether drug trials in China that involved U.S. companies possibly took place ...
Oral obesity drug with world-first mechanism of action unveiled, drawing strong on-site interestFollowing successful Phase 1 clinical results, global discussions on OVM-200 expandMeetings with over 40 ...
Equity Insider News Commentary, The scramble to build a critical-minerals supply chain outside China has become one of the ...
Hospitals and health systems are rapidly adopting AI-powered tools, connected medical devices, advanced analytics and emerging biotechnology solutions. Most organizations evaluate these technologies ...
3hon MSNOpinion
America at 250: Building the next era of prosperity
As the nation celebrates its 250th birthday, the most important question is no longer how the United States became the ...
In a world where "commercialization and criminalization are happening simultaneously," Prof. Kojo Koram explores the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results